Patients with an ApoE ϵ4 allele require lower doses of coumarin anticoagulants

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Pharmacogenetics & Genomics

• Publication date

  2005-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01213011-200502000-00002PMID 15861030
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

  2004cited by this paper
• The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

  2004cited by this paper
• Apolipoprotein E Polymorphisms and Concentration in Chronic Diseases and Drug Responses

  2000cited by this paper
• Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype.

  2000cited by this paper
• Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene

  1998cited by this paper
• A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease.

  1998cited by this paper
• The roles of vitamins D and K in bone health and osteoporosis prevention

  1997cited by this paper
• Transport of vitamin K to bone in humans.

  1996cited by this paper
• A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele

  1996cited by this paper
• Variation of Phylioquinone (Vitamin K1) Concentrations in Hemodialysis Patients

  1995cited by this paper
• The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival.

  1995cited by this paper
• The apolipoprotein E ε2 allele is associated with an increased risk of early‐onset alzheimer's disease and a reduced survival

  1995cited by this paper
• Optimal oral anticoagulant therapy in patients with mechanical heart valves.

  1995cited by this paper
• ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS Study. European Atherosclerosis Research Study.

  1994cited by this paper
• Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study.

  1994cited by this paper
• Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis.

  1993cited by this paper
• Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world

  1992cited by this paper
• Vitamin K metabolism and nutriture.

  1992cited by this paper
• Determinants of disease and disability in the elderly: The Rotterdam elderly study

  1991cited by this paper
• Apolipoprotein E genotyping by one-stage PCR.

  1991cited by this paper
• Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase.

  1990cited by this paper
• Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E.

  1987cited by this paper
• Linear Models for the Analysis of Longitudinal Studies

  1985cited by this paper
• Human apolipoprotein E isoprotein subclasses are genetically determined.

  1981cited by this paper
• The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin.

  1974cited by this paper
• Vitamin K dependent modifications of glutamic acid residues in prothrombin.

  1974cited by this paper

• Vitamin K: Metabolism, Genetic Influences, and Chronic Disease Outcomes

  2025cites this paper
• Influence of polymorphisms in CYP2C9, VKORC1, MDR1 and APOE genes on the warfarin maintenance dose in Brazilian patients.

  2023cites this paper
• A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study

  2020cites this paper
• Association between apolipoprotein E genotype and warfarin response during initial anticoagulation.

  2018cites this paper
• Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population

  2017cites this paper
• Can pharmacogenetics help patients under chronic treatment with coumarin anticoagulants?

  2016cites this paper
• Pharmacogenomics of Oral Antithrombotic Drugs.

  2016cites this paper
• Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis.

  2016cites this paper
• Pharmacogenetics of coumarin anticoagulant therapy

  2015cites this paper
• Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.

  2014cites this paper
• Pharmacogenetics role in the safety of acenocoumarol therapy

  2014cites this paper
• Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm

  2014cites this paper
• Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.

  2014cites this paper
• Resistance and sensibility to warfarin

  2014cites this paper
• Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms

  2013cites this paper
• Towards optimal dosing of coumarin derivatives: the role of pharmacogenetics

  2013cites this paper
• A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism.

  2013cites this paper
• Vitamin K nutrition, metabolism, and requirements: current concepts and future research.

  2012cites this paper
• Personalized approach of medication by indirect anticoagulants tailored to the patient—Russian context: what are the prospects?

  2012cites this paper
• Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial

  2012cites this paper
• An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease

  2012cites this paper
• Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations

  2011cites this paper
• Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes

  2011cites this paper
• Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.

  2011cites this paper
• Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions

  2011cites this paper
• The Rotterdam Study: 2012 objectives and design update

  2011cites this paper
• VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China

  2010cites this paper
• Optymalizacja leczenia antagonistami witaminy K — rola polimorfizmów genowych Optimalisation of treatment with vitamin K anatagonistsm — the role of gene polymorphisms

  2010cites this paper
• Pharmacogénétique et antivitamine K aujourd’hui : un débat ouvert

  2010cites this paper
• Pharmacogenetics of oral anticoagulant therapy.

  2010cites this paper
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population

  2010cites this paper
• [The pharmacogenetics of vitamin K antagonists: still a matter for discussion].

  2010cites this paper
• [Optimalisation of treatment with vitamin K antagonists--the role of gene polymorphisms].

  2010cites this paper
• Farmacogenética da varfarina : proposta de um algoritmo para a predição de dose

  2010cites this paper
• Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements

  2010cites this paper
• Major determinants of outcome and dosing in warfarin treatment

  2009cites this paper
• Association Between ApoE4 Allele and Deep Venous Thrombosis: A Pilot Study

  2009cites this paper
• Pharmacogenetics Strategies: From Candidate Genes to Whole-Genome Association Analysis. Exploratory or Confirmatory Studies?

  2009cites this paper
• Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans

  2008cites this paper
• Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.

  2008cites this paper
• Pharmacogenetics of Oral Anticoagulants

  2008cites this paper
• Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients.

  2008cites this paper
• Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.

  2008cites this paper
• The Rotterdam Study: objectives and design update

  2007cites this paper
• Individualizing warfarin therapy.

  2007cites this paper
• The Rotterdam Study: 2010 objectives and design update

  2007cites this paper
• Effects of CYP2C9 and VKORC1 polymorphisms and drug interactions on coumarin anticoagulation control

  2007cites this paper
• In vitro anti-inflammatory activity of 4-arylcoumarins from endophytic Streptomyces aureofaciens CMUAc130 in murine macrophage RAW 264.7 cells

  2007cites this paper
• Pharmacogenetics of warfarin: current status and future challenges

  2007cites this paper
• Estimation of Warfarin Maintenance Dose Based on VKORC1 ( (cid:1) 1639 G (cid:2) A) and CYP2C9 Genotypes

  2007cites this paper
• Factors influencing warfarin dose requirements in African-Americans.

  2007cites this paper
• Antitumor activity of 4-arylcoumarins from endophytic Streptomyces aureofaciens CMUAc130.

  2007cites this paper
• Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin

  2007cites this paper
• RETRACTED: Anti-inflammatory Activity of 4-Arylcoumarins from Endophytic Streptomyces aureofaciens CMUAc130 in Murine Macrophage RAW 264.7 Cells

  2007cites this paper
• Use of genetic and nongenetic factors in warfarin dosing algorithms.

  2007cites this paper
• Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.

  2007cites this paper
• Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.

  2007cites this paper
• Pharmacogenetics of Target Genes Across the Warfarin Pharmacological Pathway

  2006cites this paper
• Apolipoprotein E Gene Polymorphism and Allele Frequencies in the Lebanese Population

  2006cites this paper
• Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants

  2006cites this paper
• APOE genotype makes a small contribution to warfarin dose requirements.

  2006cites this paper
• Association of warfarin dose with genes involved in its action and metabolism

  2006cites this paper
• CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese.

  2006cites this paper
• Genetic influences on the response to warfarin

  2006cites this paper
• Anti-inflammatory Effects of 4-Arylcoumarins in LPS-induced Murine Macrophage RAW 264.7 Cells

  2006cites this paper
• Variantes de los genes CYP2C9 y apolipoproteína E en la respuesta individual a la warfarina

  2006cites this paper
• The interference of botanicals and nutraceuticals with the effects of antithrombotic agents: how should the available evidence be weighed?

  2005cites this paper
• The interference of botanicals and nutraceuticals with the effects of antithrombotic agents: how should the available evidence be weighed?

  2005cites this paper
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

  2005cites this paper